Literature DB >> 34386959

Site-Specific Modification of Single-Chain Affinity Ligands for Fluorescence Labeling, Radiolabeling, and Bioconjugation.

Boya Zhang1,2, Sachith M Vidanapathirana1,2, Colin F Greineder3,4.   

Abstract

Single-chain protein affinity ligands are recombinant polypeptides that recreate the antigen-binding site of parental, monoclonal antibodies (mAbs) or present unique binding surfaces derived from display technologies, computational design, or other approaches. These diverse ligands have several advantages over full-length mAbs as agents for delivery of small molecule, protein, and nanoparticle cargoes to desired sites in the body. However, they present unique challenges for modification and bioconjugation. Fusion of a LPXTGG motif, or "sortag," and a 5-amino acid, flexible linker to the C-terminus of these affinity ligands enables high-efficiency transpeptidation by the bacterial enzyme, Sortase A, and site-specific addition of fluorophores, radiolabels, or functional groups for oriented and stoichiometrically controlled bioconjugation. We describe in detail this method and address several challenges and pitfalls in the purification and characterization of modified single-chain affinity ligands.
© 2021. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Affinity ligand; Bioconjugation; Labeling; Site-specific modification; Sortase

Mesh:

Substances:

Year:  2021        PMID: 34386959      PMCID: PMC9289842          DOI: 10.1007/978-1-0716-1617-8_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  32 in total

1.  A general strategy for the evolution of bond-forming enzymes using yeast display.

Authors:  Irwin Chen; Brent M Dorr; David R Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-22       Impact factor: 11.205

Review 2.  Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy.

Authors:  Andreas Plückthun
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015       Impact factor: 13.820

Review 3.  Aligning physics and physiology: Engineering antibodies for radionuclide delivery.

Authors:  Wen-Ting K Tsai; Anna M Wu
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-15       Impact factor: 1.921

Review 4.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

5.  Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humans.

Authors:  Colin F Greineder; Elizabeth D Hood; Anning Yao; Makan Khoshnejad; Jake S Brenner; Ian H Johnston; Mortimer Poncz; Claudia Gottstein; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

6.  Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions.

Authors:  Carla P Guimaraes; Martin D Witte; Christopher S Theile; Gunes Bozkurt; Lenka Kundrat; Annet E M Blom; Hidde L Ploegh
Journal:  Nat Protoc       Date:  2013-08-29       Impact factor: 13.491

7.  Site-specific N-terminal labeling of proteins using sortase-mediated reactions.

Authors:  Christopher S Theile; Martin D Witte; Annet E M Blom; Lenka Kundrat; Hidde L Ploegh; Carla P Guimaraes
Journal:  Nat Protoc       Date:  2013-08-29       Impact factor: 13.491

8.  Site-specific protein labeling via sortase-mediated transpeptidation.

Authors:  Maximilian Wei-Lin Popp; John M Antos; Hidde L Ploegh
Journal:  Curr Protoc Protein Sci       Date:  2009-04

Review 9.  The pharmacology and therapeutic applications of monoclonal antibodies.

Authors:  María Sofía Castelli; Paul McGonigle; Pamela J Hornby
Journal:  Pharmacol Res Perspect       Date:  2019-12

10.  Bivalent engagement of endothelial surface antigens is critical to prolonged surface targeting and protein delivery in vivo.

Authors:  R Yu Kiseleva; P G Glassman; K M LeForte; L R Walsh; C H Villa; V V Shuvaev; J W Myerson; P A Aprelev; O A Marcos-Contreras; V R Muzykantov; C F Greineder
Journal:  FASEB J       Date:  2020-08-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.